Business
Veracyte Announces New Data at AUA 2026 Highlighting the Power of the Decipher Portfolio to Advance Personalized Care in Urologic Cancers
Studies demonstrate clinical utility of Decipher Bladder molecular subtyping in bladder cancer and the expanding impact of Decipher Prostate in studies using
About this update from Veracyte, Inc.
[{"type":"text","content":"\nStudies demonstrate clinical utility of Decipher Bladder molecular subtyping in bladder cancer and the expanding impact of Decipher Prostate in studies using real-world data\n\n\n SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--\nVeracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, announced today that more than 15 studies focused on the Decipher portfolio will be presented at the 2026 American Urological Association (AUA) Annual Meeting, taking place May 15-18 in Washington, D.C. The data showcases the growing impact of the Decipher Bladder and Prostate tests to inform more personalized patient care. The studies provide insights into molecular subtypes associated with patient outcomes in bladder cancer and feature national-scale real‑world data analyses in prostate cancer that demonstrate how Decipher Prostate informs treatment decisions. Additional real‑world data from the Decipher Genomics Research for Intelligent Discovery (GRID) research tool continues to fuel the flywheel of evidence in urologic cancers through ongoing research studies.\n\n\n“These studies underscore the power of Veracyte’s Diagnostics Platform to generate clinically meaningful evidence at scale,” said Elai Davicioni, Ph.D., Veracyte’s medical director, Urology. “With more than a decade of data in our Decipher GRID tool, we are accelerating research to drive new discoveries that help clinicians better personalize care and improve outcomes for patients.”\n\n\nAt this year’s meeting, during Bladder Cancer Awareness month in May, several studies will highlight the clinical relevance of molecular subtyping in bladder cancer using the Decipher Bladder test, including its role in guiding treatment decisions and predicting outcomes. Key presentations include:\n\n\n\n\nTitle:\n\n\n\n\n\n\nMolecular Characterization and a Showcase Clinical Study on Treatment De-escalation for Luminal Favorable Muscle-Invasive Bladder Cancer\n\n\n\n\n\n\n\n\nPresenter:\n\n\n\n\n\n\nMelissa Moran, DO, Rutgers Robert Wood Johnson University Hospital\n\n\n\n\n\n\n\n\nFormat:\n\n\n\n\n\n\nPoster\n\n\n\n\n\n\n\n\nAbstract #:\n\n\n\n\n\n\nIP35-15\n\n\n\n\n\n\n\n\nDate/Time:\n\n\n\n\n\nSaturday, May 16, 2026, 9:30 – 11:30 AM ET\n\n\n\nLocation:\n\n\n\n\n\n147A\n\n\n\n \n\n\n\nTitle:\n\n\n\n\n\n\nNon-luminal molecular subtypes demonstrate highest complete response rates afte...